Recent innovations in mRNA vaccines
Highlights • mRNA vaccines continue to show promise as prophylactic and therapeutic vaccines. • Clinical data with mRNA cancer vaccines indicate they are tolerated and immunogenic. • Self-amplifying mRNA vaccine are potent in larger animal at low doses (50 μg). • A broader package of human clinical...
Gespeichert in:
Veröffentlicht in: | Current opinion in immunology 2016-08, Vol.41, p.18-22 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 22 |
---|---|
container_issue | |
container_start_page | 18 |
container_title | Current opinion in immunology |
container_volume | 41 |
creator | Ulmer, Jeffrey B Geall, Andrew J |
description | Highlights • mRNA vaccines continue to show promise as prophylactic and therapeutic vaccines. • Clinical data with mRNA cancer vaccines indicate they are tolerated and immunogenic. • Self-amplifying mRNA vaccine are potent in larger animal at low doses (50 μg). • A broader package of human clinical proof of principle still needs to be developed. |
doi_str_mv | 10.1016/j.coi.2016.05.008 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1815704505</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0952791516300486</els_id><sourcerecordid>1815704505</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-f01495542cfbaf6ef8cad6beb13db032ec8af6ff9e459fb1e63b260b99cd3d873</originalsourceid><addsrcrecordid>eNqNkctKxDAUhoMoOl4ewI0MuHHTenJrUwRhGLzBoDDqOrTpCWTspNq0A_P2Zhh14UJc5eTw_f_iO4ScUkgp0OxykZrWpSyOKcgUQO2QEVV5kQDP2S4ZQSFZkhdUHpDDEBYAICWHfXLAcibiR4zI-RwN-n7svG9XZe9aH-I8Xs4fJ-NVaYzzGI7Jni2bgCdf7xF5vb15md4ns6e7h-lklhghaJ9YoKKQUjBjq9JmaJUp66zCivK6As7QqLi2tkAhC1tRzHjFMqiKwtS8Vjk_Ihfb3veu_Rgw9HrpgsGmKT22Q9BUUZmDkCD_gzKlhMwgonSLmq4NoUOr3zu3LLu1pqA3GvVCR416o1GD1FFjzJx91Q_VEuufxLe3CFxtAYw-Vg47HYxDb7B2HZpe17Hwr_rrX2nTOO9M2bzhGsOiHTofRWuqA9Ognzd33JyRZhxAqIx_AlIWlf8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1812884560</pqid></control><display><type>article</type><title>Recent innovations in mRNA vaccines</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Ulmer, Jeffrey B ; Geall, Andrew J</creator><creatorcontrib>Ulmer, Jeffrey B ; Geall, Andrew J</creatorcontrib><description>Highlights • mRNA vaccines continue to show promise as prophylactic and therapeutic vaccines. • Clinical data with mRNA cancer vaccines indicate they are tolerated and immunogenic. • Self-amplifying mRNA vaccine are potent in larger animal at low doses (50 μg). • A broader package of human clinical proof of principle still needs to be developed.</description><identifier>ISSN: 0952-7915</identifier><identifier>EISSN: 1879-0372</identifier><identifier>DOI: 10.1016/j.coi.2016.05.008</identifier><identifier>PMID: 27240054</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Allergy and Immunology ; Animals ; Humans ; RNA, Messenger - genetics ; Vaccines, DNA - genetics ; Vaccines, DNA - immunology</subject><ispartof>Current opinion in immunology, 2016-08, Vol.41, p.18-22</ispartof><rights>2016 Elsevier Ltd</rights><rights>Copyright © 2016 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-f01495542cfbaf6ef8cad6beb13db032ec8af6ff9e459fb1e63b260b99cd3d873</citedby><cites>FETCH-LOGICAL-c441t-f01495542cfbaf6ef8cad6beb13db032ec8af6ff9e459fb1e63b260b99cd3d873</cites><orcidid>0000-0001-9930-3316</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0952791516300486$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27240054$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ulmer, Jeffrey B</creatorcontrib><creatorcontrib>Geall, Andrew J</creatorcontrib><title>Recent innovations in mRNA vaccines</title><title>Current opinion in immunology</title><addtitle>Curr Opin Immunol</addtitle><description>Highlights • mRNA vaccines continue to show promise as prophylactic and therapeutic vaccines. • Clinical data with mRNA cancer vaccines indicate they are tolerated and immunogenic. • Self-amplifying mRNA vaccine are potent in larger animal at low doses (50 μg). • A broader package of human clinical proof of principle still needs to be developed.</description><subject>Allergy and Immunology</subject><subject>Animals</subject><subject>Humans</subject><subject>RNA, Messenger - genetics</subject><subject>Vaccines, DNA - genetics</subject><subject>Vaccines, DNA - immunology</subject><issn>0952-7915</issn><issn>1879-0372</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkctKxDAUhoMoOl4ewI0MuHHTenJrUwRhGLzBoDDqOrTpCWTspNq0A_P2Zhh14UJc5eTw_f_iO4ScUkgp0OxykZrWpSyOKcgUQO2QEVV5kQDP2S4ZQSFZkhdUHpDDEBYAICWHfXLAcibiR4zI-RwN-n7svG9XZe9aH-I8Xs4fJ-NVaYzzGI7Jni2bgCdf7xF5vb15md4ns6e7h-lklhghaJ9YoKKQUjBjq9JmaJUp66zCivK6As7QqLi2tkAhC1tRzHjFMqiKwtS8Vjk_Ihfb3veu_Rgw9HrpgsGmKT22Q9BUUZmDkCD_gzKlhMwgonSLmq4NoUOr3zu3LLu1pqA3GvVCR416o1GD1FFjzJx91Q_VEuufxLe3CFxtAYw-Vg47HYxDb7B2HZpe17Hwr_rrX2nTOO9M2bzhGsOiHTofRWuqA9Ognzd33JyRZhxAqIx_AlIWlf8</recordid><startdate>20160801</startdate><enddate>20160801</enddate><creator>Ulmer, Jeffrey B</creator><creator>Geall, Andrew J</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>7TM</scope><scope>H94</scope><orcidid>https://orcid.org/0000-0001-9930-3316</orcidid></search><sort><creationdate>20160801</creationdate><title>Recent innovations in mRNA vaccines</title><author>Ulmer, Jeffrey B ; Geall, Andrew J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-f01495542cfbaf6ef8cad6beb13db032ec8af6ff9e459fb1e63b260b99cd3d873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Allergy and Immunology</topic><topic>Animals</topic><topic>Humans</topic><topic>RNA, Messenger - genetics</topic><topic>Vaccines, DNA - genetics</topic><topic>Vaccines, DNA - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ulmer, Jeffrey B</creatorcontrib><creatorcontrib>Geall, Andrew J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Current opinion in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ulmer, Jeffrey B</au><au>Geall, Andrew J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recent innovations in mRNA vaccines</atitle><jtitle>Current opinion in immunology</jtitle><addtitle>Curr Opin Immunol</addtitle><date>2016-08-01</date><risdate>2016</risdate><volume>41</volume><spage>18</spage><epage>22</epage><pages>18-22</pages><issn>0952-7915</issn><eissn>1879-0372</eissn><abstract>Highlights • mRNA vaccines continue to show promise as prophylactic and therapeutic vaccines. • Clinical data with mRNA cancer vaccines indicate they are tolerated and immunogenic. • Self-amplifying mRNA vaccine are potent in larger animal at low doses (50 μg). • A broader package of human clinical proof of principle still needs to be developed.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>27240054</pmid><doi>10.1016/j.coi.2016.05.008</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0001-9930-3316</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0952-7915 |
ispartof | Current opinion in immunology, 2016-08, Vol.41, p.18-22 |
issn | 0952-7915 1879-0372 |
language | eng |
recordid | cdi_proquest_miscellaneous_1815704505 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Allergy and Immunology Animals Humans RNA, Messenger - genetics Vaccines, DNA - genetics Vaccines, DNA - immunology |
title | Recent innovations in mRNA vaccines |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T16%3A00%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recent%20innovations%20in%20mRNA%20vaccines&rft.jtitle=Current%20opinion%20in%20immunology&rft.au=Ulmer,%20Jeffrey%20B&rft.date=2016-08-01&rft.volume=41&rft.spage=18&rft.epage=22&rft.pages=18-22&rft.issn=0952-7915&rft.eissn=1879-0372&rft_id=info:doi/10.1016/j.coi.2016.05.008&rft_dat=%3Cproquest_cross%3E1815704505%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1812884560&rft_id=info:pmid/27240054&rft_els_id=S0952791516300486&rfr_iscdi=true |